Literature DB >> 27819379

7th Brazilian Guideline of Arterial Hypertension: Presentation

M v b Malachias.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27819379      PMCID: PMC5319461          DOI: 10.5935/abc.20160140

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


× No keyword cloud information.
Declaration of potential conflict of interest of authors/collaborators of 7th Brazilian Guideline of Arterial Hypertension If the last three years the author/developer of the Guidelines:

Introduction

On behalf of the Brazilian Society of Cardiology, Brazilian Society of Hypertension and Brazilian Society of Nephrology, I present to you the 7th Brazilian Guideline of Arterial Hypertension, result of the joint work of an expert team of renowned professionals appointed by their respective medical societies. The production of this new guideline was necessary to update the knowledge accumulated over the past years, considering the Brazilian reality and clinical practice. The guidance and recommendations contained in this document reflect the evidence of the effectiveness of the interventions. The present text does not deal specifically with cost-effectiveness analyses. The major objective of the medical societies and authors is to guide health professionals on the preventive measures and care for individuals with arterial hypertension, aiming at reducing the complications of arterial hypertension, considered the major risk factor for cardiovascular disease. The following table was used as reference for the grades of recommendation and levels of evidence. Marcus Vinícius Bolívar Malachias Abbreviations of the Brazilian Guideline of AH

Declaration of potential conflict of interest of authors/collaborators of 7th Brazilian Guideline of Arterial Hypertension If the last three years the author/developer of the Guidelines:

Names Membersof the PolicyParticipated in clinical studies and / or experimental trials supported by pharmaceutical or equipment related to the guideline in questionHas spoken at events or activities sponsored by industry related to the guideline in questionIt was (is) advisory board member or director of a pharmaceutical or equipmentCommittees participated in completion of research sponsored by industryPersonal or institutional aid received from industryProduced scientific papers in journals sponsored by industryIt shares theindustry
Alexandre AlessiNoNoNoNoNoNoNo
Ana Cristina Simões e SilvaNoNoNoNoNoNoNo
Andrea Araujo BrandãoNovartis Biolab, Daiichi Sankyo, Novartis, ServierNoNoBiolab, Daiichi Sankyo, Novartis, ServierBiolab, Novartis, Servier, SEMNo
Angela Maria Geraldo PierinNoNoNoNoNoNoNo
Antonio Carlos Cordeiro JúniorNoNoNoNoNoNoNo
Armando da Rocha NogueiraNoNoNoNoNoNoNo
Audes Diógenes FeitosaNoNoNoNoNoNoNo
Carlos Alberto MachadoNoNoNoNoNoNoNo
Carlos Eduardo Poli de FigueiredoNoNoNoNoNoNoNo
Celso AmodeoServierNoBiolabServierAche, Servier, Merck Serona, AstraZeneca, BiolabNovartisNo
Cibele Isaac Saad RodriguesNoNoNoNoNoNoNo
Cláudia Lúcia de Moraes ForjazNoNoNoNoNoNoNo
Fernando Antonio AlmeidaNoNoNoNoNoNoNo
Frida Liane PlavnikNoNoNoNoNoNoNo
Paulo César Veiga JardimNoBiolab - Servier - Novartis - AchéNoNoServier, Ministério da Ciência, CNPqNoNo
Deborah MaltaNoNoNoNoNoNoNo
Décio Mion JúniorNoNoNoNoNoNoNo
Dilma do Socorro Moraes de SouzaNoNoNoNoNoNoNo
Eduardo Barbosa CoelhoNoNoNoNoNoNoNo
Eduardo Costa Duarte BarbosaNovartis, Servier, MSD, Takeda, Amgen, AstraZeneca, PfizerNoNoNoServier, BiolabNoNo
Elizabeth MuxfeldtNoNoNoNoNoNoNo
Emilton Lima JúniorNoBiolabNoNoNoNoNo
Fernanda Consolim ColomboAche,NovartisDaiichi Sankyo,Servier,Merck,Boehringer, NovartisNoNoNoLibbs,MerckNo
Fernando NobreNoNovartis Biociências,Merck Soreno,SEM,Sanofi-Aventi,Libbs FarmacêuticaNoNovartis Biociências,Libbs FarmacêuticaSanofi-Aventis,Libbs FarmacêuticaSEM,Novartis Biociências,Biolab,Torrent,Bayer,Libbs FarmacêuticaNo
Flávio Antonio de Oliveira BorelliNoServierNoNoNoNoNo
Gil Fernando SallesNoNoNoNoNoNoNo
Gilson Soares FeitosaNoNoNoNoNoNoNo
Giovanio Vieira da SilvaNoNoNoNoNoNoNo
Guido Bernardo Aranha RositoNoNoNoNoNoNoNo
Heitor Moreno JúniorNoNoNoNoNoNoNo
Heno Ferreira LopesNoNoNoNoNoNoNo
Isabel Cristina Britto GuimarãesNoNoNoNoNoNoNo
Ivan Carlos AntonelloNoNoNoNoNoNoNo
José Fernando Vilela MartimNoNoNoNoNoNoNo
José Marcio RibeiroNoBiolab,B Ingelheim,PfizerNoNoServierNoNo
Juan Yugar ToledoNoNoNoNoNoNoNo
Leda Aparecida Daud LotaifNoNoNoNoNoNoNo
Lilian Soares da CostaNoNoNoNoNoNoNo
Lucélia Batista Neves Cunha MagalhaesNoNoNoNoNoNoNo
Luciano Ferreira DragerNoNoNoNoNoNoNo
Luis Cuadrado MartinsNoNoNoNoNoNoNo
Luiz Aparecido BortolottoNovartisServier, Biolab, NovartisNoNoNoBiolab, Novartis, Servier, BaldacciNo
Luiz Carlos BodaneseSanofi, GSK, RocheSanofi, Novartis, BoehringerNoServier, Sanofi, ANGEMSafoni, ANGEM, GSKPfizerNo
Luiz Cesar Nazario ScalaNoNoNoNoNoNoNo
Marcia Maria Godoy GowdakNoNoNoNoNoNoNo
Marcia Regina Simas Torres KleinNoNoNoNoNoNoNo
Marco Antonio Mota GomesNovartis, AstraZeneca, Biolab, Daiichi Sankyo,Takeda, Torrent, Libbs, Pfizer, Janssen, Cardios, OmronNoNoNoNoNoNo
Marcus Vinícius Bolívar MalachiasNoBiolab, Chiesi, Medley-Sanofi, Novartis, PfizerNoNoNoBiolab, Boehringer-Ingelheim, NovartisNo
Maria Eliane MagalhãesAstraZeneca, Novartis, Sanofi-Aventis, Daiichi SankyoAstraZeneca, Pfizer, Sanofi-Aventis, MSD, ChiesiNoNoAstraZeneca, Pfizer, MSD, NovartisNoNo
Maria Regina TorloniNoNoNoNoNoNoNo
Maria Rita de Figueiredo Lemos BortolottoNoNoNoNoNoNoNo
Mário Fritsch Toros NevesNovartis, Servier, AstraZeneca, Pfizer, Sanofi, LibbsNoNovartis, ServierNoNoNoNo
Miguel GusNoNoNoNoNoNoNo
Nelson SassNoNoNoNoNoNoNo
Osni Moreira FilhoNoNoNoNoBiolab, Pfizer, NovartisEMSNo
Oswaldo Passarelli JúniorBiolab, Novartis, Daiichi Sankyo      
Paulo Koch NogueiraNoNoNoNoNoNoNo
Roberto Dischinger MirandaAché, Astra Zeneca, Bayer, Biolab, Boeringher Ingelheim, MSD, Novartis, PfizerNoBayer, Novartis, PfizerNoNoNoNo
Roberto Jorge da Silva FrancoNoNoNoNoNoNoNo
Rogério Baumgratz de PaulaNoNoNoNoNoNoNo
Rui Manuel dos Santos PóvoaNoNoNoNoNoNoNo
Sandra FuchsNoNoNoNoNoNoNo
Sebastião Ferreira FilhoNoNoNoNoNoNoNo
Sergio KaiserBristol-Myers-Squibb, Novaquimica, AbbottNoNoNoNoNoNo
Thiago de Souza Veiga JardimNovartis, Astra ZenecaBiolab, Daiichi Sankyo, Novartis, Astra Zeneca, Servier  Daiichi Sankyo, ServierDaiichi Sankyo 
Vera KochNoNoNoNoNoNoNo
Victor MatsudoNoNoNoInstituto ActigraphNoNoNo
Weimar Kunz Sebba Barroso de SouzaAmgen, AstraZeneca, Bayer, Boehringer, Jonhson & Johnson, Libbs, Lilly, Merck Sharp Dhome, Novartis, Pfizer, Roche, Sanofi Aventis, Daiichi Sankyo, TorrentAstraZeneca, Biolab, Boehringer, Lilly, Servier, TorrentNoNoNoNoNo
Wille Oigman CobreiLibbsNoNoNoNoNoNo
Grades of recommendation:
Class I: Conditions to which there is conclusive evidence or at least general consensus concerning the safety and usefulness/efficacy of the intervention;
Class II: Conditions to which there is conflicting evidence and/or disagreement of opinion concerning the safety and usefulness/efficacy of the intervention;
Class IIa: Evidence/opinion in favor of the intervention. Most experts agree;
Class IIb: Less well-established safety and usefulness/efficacy, without predominance of favorable opinions on the intervention;
Class III: Conditions to which there is evidence and/or consensus that the intervention is not useful/effective, and, in some cases, even harmful.
Levels of evidence:
Level A: Data derived from multiple consistent randomized controlled clinical trials, and/or a robust meta-analysis of randomized clinical trials;
Level B: Data derived from a less robust meta-analysis, one single randomized trial or non- randomized trials (observational);
Level C: Data derived from consensual expert opinion.
We hope the concepts expressed in this guideline can be widely spread to a better and more comprehensive care of individuals with arterial hypertension.

Abbreviations of the Brazilian Guideline of AH

ABIAnkle-brachial indexICUIntensive care unit
ABPMAmbulatory blood pressure monitoringIDFInternational Diabetes Federation
ACAbdominal circumferenceIGF-1Insulin-like growth factor 1
ACCAmerican College of CardiologyIHDIschemic heart diseases
ACEIAngiotensin-converting-enzyme inhibitorIMTIntima-media thickness
ACTHAdrenocorticotropinIPEMsState Departments of Weights and Measures
AHArterial hypertensionISHIsolated systolic hypertension
AHAAmerican Heart AssociationIVIntravenous
AHIApnea-hypopnea indexLVHLeft ventricular hypertrophy
AKIAcute kidney injuryLVMILeft ventricular mass index
AldoAldosteroneMHMasked hypertension
AMIAcute myocardial infarctionMIMyocardial infarction
APAAldosterone-producing adenomaMIBGMetaiodobenzylguanidine
APEAcute pulmonary edemaMRIMagnetic resonance imaging
ARBAngiotensin II receptor blockerMSMetabolic syndrome
BBBeta-blockerNKFNational Kidney Foundation
BMIBody mass indexNPTNon-pharmacological treatment
BPBlood pressureOSAHSObstructive sleep apnea-hypopnea syndrome
CADCoronary artery diseasePADPeripheral arterial disease
CAHChronic arterial hypertensionPEPreeclampsia
CbVDCerebrovascular diseasesPHPrehypertension
CCBCalcium-channel blockerPHAPrimary hyperaldosteronism
CDCCenters for Disease Control and PreventionPHEOPheochromocytoma
CHFCongestive heart failurePNSBrazilian National Health Survey
CKDChronic kidney diseasePOFSurvey on Family Income
COPDChronic obstructive pulmonary diseasePPPulse pressure
CPAPContinuous positive airway pressurePRAPlasma renin activity
CrClCreatinine clearancePSNSParasympathetic nervous system
CSCushing’s syndromePTHParathormone
CTComputed tomographyPVRPeripheral vascular resistance
CVCardiovascularPWVPulse wave velocity
CVDCardiovascular diseaseRAASRenin-angiotensin-aldosterone system
CVRFCardiovascular risk factorRAHResistant arterial hypertension
DAHDiastolic arterial hypertensionRBMLQBrazilian Legal Metrology and Quality Network
DBPDiastolic blood pressureRFRisk factor
DHADocosahexaenoic acidRVAHRenovascular arterial hypertension
DIUDiureticSAHSystemic arterial hypertension
DMDiabetes mellitusSBPSystolic blood pressure
EPAEicosapentaenoic acidSNPSodium nitroprusside
GFRGlomerular filtration rateSNSSympathetic nervous system
GHGrowth hormoneSUSBrazilian Unified Health Care System
GRSGlobal Risk ScoreTCTotal cholesterol
HbA1cGlycated hemoglobinTIATransient ischemic attack
HBPMHome blood pressure monitoringTODTarget-organ damage
HCHypertensive crisisTSHThyroid stimulating hormone
HDHypertensive diseasesUACRUrine albumin/creatinine ratio
HDL-CHigh-density lipoprotein cholesterolUSUltrasonography
HEHypertensive emergencyVIGITELSurveillance for Risk Factors and Protection Against Chronic Diseases via Telephone Inquiry
HFHeart failureWCEWhite-coat effect
HRHeart rateWCHWhite-coat hypertension
HUHypertensive urgency 
  16 in total

1.  Prevalence and factors associated with arterial hypertension in a Brazilian rural working population.

Authors:  Luciane Bresciani Salaroli; Monica Cattafesta; Glenda Blaser Petarli; Sarah Aparecida Vieira Ribeiro; Ana Cristina de Oliveira Soares; Eliana Zandonade; Olívia Maria de Paula Alves Bezerra; José Geraldo Mill
Journal:  Clinics (Sao Paulo)       Date:  2020-08-10       Impact factor: 2.365

2.  Effects of chronic type 5 phosphodiesterase inhibition on penile microvascular reactivity in hypertensive patients with erectile dysfunction: a randomized crossover placebo-controlled trial.

Authors:  Valéria Verri; Alessandro R Nascimento; Andrea A Brandao; Eduardo Tibirica
Journal:  J Hum Hypertens       Date:  2020-05-04       Impact factor: 3.012

3.  Physical Activity Counseling for Adults with Hypertension: A Randomized Controlled Pilot Trial.

Authors:  Altieres E Sousa Junior; Geovani A D Macêdo; Daniel Schwade; Júlio Sócrates; José W Alves; Luiz F Farias-Junior; Yuri A Freire; Telma M A M Lemos; Rodrigo A V Browne; Eduardo C Costa
Journal:  Int J Environ Res Public Health       Date:  2020-08-21       Impact factor: 3.390

4.  Coconut Oil Supplementation Does Not Affect Blood Pressure Variability and Oxidative Stress: A Placebo-Controlled Clinical Study in Stage-1 Hypertensive Patients.

Authors:  Francisco A O Júnior; Clara R Ruiz; Yohanna de Oliveira; Marco A V Barros; Alexandre S Silva; Maria S B Santos; Vinícius J B Martins; Camille M Balarini; Valdir A Braga
Journal:  Nutrients       Date:  2021-02-28       Impact factor: 5.717

5.  Beetroot juice intake with different amounts of nitrate does not change aerobic exercise-mediated responses in heart rate variability in hypertensive postmenopausal women: A randomized, crossover and double-blind study.

Authors:  Victor Hugo V Carrijo; Ana Luiza Amaral; Igor M Mariano; Tállita Cristina F de Souza; Jaqueline P Batista; Erick P de Oliveira; Guilherme M Puga
Journal:  J Exerc Sci Fit       Date:  2020-12-18       Impact factor: 3.103

6.  Hemodynamics and cardiac autonomic modulation after an acute concurrent exercise circuit in older individuals with pre- to established hypertension.

Authors:  Ricardo Cordeiro; Pedro Augusto Mira; Walace Monteiro; Felipe Cunha; Mateus C Laterza; Linda S Pescatello; Daniel G Martinez; Paulo Farinatti
Journal:  Clinics (Sao Paulo)       Date:  2021-01-20       Impact factor: 2.365

7.  Do we AGREE on the targets of antihypertensive drug treatment in older adults: a systematic review of guidelines on primary prevention of cardiovascular diseases.

Authors:  Jonathan M K Bogaerts; Leonie M von Ballmoos; Wilco P Achterberg; Jacobijn Gussekloo; Sven Streit; Milly A van der Ploeg; Yvonne M Drewes; Rosalinde K E Poortvliet
Journal:  Age Ageing       Date:  2022-01-06       Impact factor: 10.668

8.  Acute effects of different resistance training loads on cardiac autonomic modulation in hypertensive postmenopausal women.

Authors:  Arthur F Vale; Juliana A Carneiro; Paulo C V Jardim; Thiago V Jardim; James Steele; James P Fisher; Paulo Gentil
Journal:  J Transl Med       Date:  2018-08-30       Impact factor: 5.531

9.  Arterial stiffness in type 2 diabetes: determinants and indication of a discriminative value.

Authors:  Clara Italiano Monteiro; Rodrigo Polaquini Simões; Cássia Luz Goulart; Claudio Donisete da Silva; Audrey Borghi-Silva; Renata Gonçalves Mendes
Journal:  Clinics (Sao Paulo)       Date:  2021-02-22       Impact factor: 2.365

10.  Factors Associated with the Occurrence of Arterial Hypertension in Industry Workers of State of Rio Grande do Sul, Brazil.

Authors:  Paula Brustolin Xavier; Anderson Garcez; Gabriela Herrmann Cibeira; Antonino Germano; Maria Teresa Anselmo Olinto
Journal:  Arq Bras Cardiol       Date:  2021-09       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.